2019-11-15T14:13:58-06:00 2018-12-31 560747981 DIXON HUGHES GOODMAN LLP 901 EAST CARY STREET SUITE 1000 RICHMOND VA 23219 990 2018-01-01 521986675 FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC FOUN 3014025311 11400 ROCKVILLE PIKE NO 600 NORTH BETHESDA MD 20852 MARIA C FREIRE PHD PRESIDENT 3014025311 2019-11-15 1 LAKRISHA J WATSON P01677333 8042827636 2019-11-15 4.28.226.33 2019-11-15 13:56:04 ES P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 3CD412B09983E39150554DEC6362464A9D6A3E5C 2018 2020-03-31 21:24:44Z MARIA C FREIRE PHD 11400 ROCKVILLE PIKE NO 600 NORTH BETHESDA MD 20852 153516193 0 X HTTP://WWW.FNIH.ORG X 1996 MD THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) CREATES AND LEADS ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES. 25 24 65 0 0 42795 61322159 60444618 111660 64723 1398198 2926669 46023 21286 62878040 63457296 34963149 19403180 0 0 7128157 8639303 0 78000 221918 14572507 14072429 56663813 42192912 6214227 21264384 120432415 142893974 9944796 12991167 110487619 129902807 X SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH. THE BOARD HAS AN EXECUTIVE COMMITTEE WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS. 0 0 34161888 18522487 64723 SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPSPROGRAM ONE - RESEARCH PARTNERSHIPS -INVESTIGATING NEW TREATMENTS FOR LUNG CANCER PATIENTSSHORTNESS OF BREATH. EXHAUSTION. LOSS OF APPETITE. THESE ARE JUST SOME OF THE SYMPTOMS EXPERIENCED BY PATIENTS WITH LUNG AND BRONCHIAL CANCER, WHICH REMAINS THE SECOND MOST COMMON CANCER DIAGNOSIS IN THE UNITED STATES ACCORDING TO THE NATIONAL CANCER INSTITUTE (NCI). ABOUT 85 PERCENT OF THOSE DIAGNOSED HAVE NON-SMALL CELL LUNG CANCER, A DISEASE IN WHICH CANCER CELLS FORM IN THE TISSUES OF THE LUNG.IN 2018, THE FNIH, NCI AND PARTNERS PREPARED FOR A MAJOR EXPANSION OF THE LUNG CANCER MASTER PROTOCOL (LUNG-MAP) CLINICAL TRIAL. THE TRIAL PREVIOUSLY TESTED TREATMENTS FOR PEOPLE WITH ADVANCED STAGE SQUAMOUS CELL LUNG CANCER. IT IS NOW OPEN TO PATIENTS WITH ALL TYPES OF ADVANCED STAGE NON-SMALL CELL LUNG CANCER. THIS DEVELOPMENT WILL ENABLE THOUSANDS OF NEW PATIENTS TO ENROLL IN LUNG-MAP, JOINING THE MORE THAN 1,800 PATIENTS, LIKE ANNIE BURKE, ALREADY PARTICIPATING AT 640 U.S. MEDICAL CENTERS AND COMMUNITY HOSPITALS ACROSS THE COUNTRY.LAUNCHED IN 2014, LUNG-MAP IS THE FIRST MAJOR NCI CANCER TRIAL TO TEST MULTIPLE CANCER TREATMENTS SIMULTANEOUSLY UNDER ONE "UMBRELLA" DESIGN. THIS PIONEERING RESEARCH MODEL IS MORE FLEXIBLE AND FASTER THAN TRADITIONAL CLINICAL TRIALS AS IT ENABLES RESEARCHERS TO SHARE ONE TRIAL STRUCTURE AND RECRUITMENT PROCESS. PATIENTS ARE TESTED ONCE FOR MORE THAN 200 CANCER-RELATED GENETIC ALTERATIONS BEFORE THEY ARE ASSIGNED TO INVESTIGATIONAL TREATMENT STUDIES BASED ON THEIR UNIQUE TUMOR PROFILE. PATIENTS WITHOUT A MATCHING GENETIC ALTERATION FOR A CORRESPONDING THERAPY WITHIN LUNG-MAP ARE PLACED ON AN IMMUNOTHERAPY REGIME."A GREAT THING ABOUT THE LUNG-MAP DESIGN IS THAT THE PATIENTS CAN MOVE FROM ONE STUDY TO THE NEXT TO THE NEXT," SAID JESSICA JORDAN, RESEARCH COORDINATOR, VA CONNECTICUT HEALTHCARE SYSTEMS. "EVERY SINGLE STUDY THESE DAYS REQUIRES TISSUE. WE ONLY HAVE TO SUBMIT ONE BLOCK OF TISSUE AND A PATIENT IS POTENTIALLY ABLE TO RECEIVE MORE THAN ONE LINE OF TREATMENT ON THE TRIAL IF THEIR GENERAL HEALTH ALLOWS. THAT'S THE MAJOR BENEFIT."THE TRIAL HAS ALREADY COMPLETED SEVEN OUT OF 10 LAUNCHED STUDIES, WITH TWO MORE SUB-STUDIES SCHEDULED TO OPEN IN 2019, OFFERING PATIENTS A PERSONALIZED APPROACH TO FINDING THE INVESTIGATIONAL DRUGS THAT WILL FIGHT THEIR CANCER. IMPROVE DIAGNOSIS OF KIDNEY INJURYIN 2018, THE FNIH BIOMARKERS CONSORTIUM ACHIEVED AN UNPRECEDENTED MILESTONE BY RECEIVING THE FIRST EVER QUALIFICATION OF A CLINICAL SAFETY BIOLOGICAL MARKER (BIOMARKER) AWARDED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA). THE QUALIFICATION APPLIES TO A COMPOSITE MEASURE OF SIX URINE BIOMARKERS THAT RELIABLY CHANGE IN RESPONSE TO DRUG-INDUCED KIDNEY INJURY PRIOR TO IRREVERSIBLE DAMAGE AND EARLIER THAN TRADITIONAL BIOMARKERS. THIS SET OF BIOMARKERS CAN NOW BE USED TO AID IN THE DETECTION OF ACUTE KIDNEY INJURY IN HEALTHY VOLUNTEERS DURING EARLY PHASE CLINICAL TRIALS. IT WILL HELP IMPROVE THE DEVELOPMENT OF SAFE AND EFFECTIVE MEDICINES FOR PATIENTS WHERE CONCERN HAS BEEN RAISED THAT AN INVESTIGATIONAL DRUG MAY CAUSE KIDNEY INJURY.THIS MAJOR MILESTONE WAS MADE POSSIBLE BY THE RELENTLESS EFFORTS OF GOVERNMENT, NOT-FOR-PROFIT AND INDUSTRY PARTNERS SHARING INTELLECTUAL AND FINANCIAL RESOURCES TO FAST-TRACK THE DEVELOPMENT OF THESE CRITICAL BIOMARKERS. THE PATHWAY SET FORTH BY THE TEAM MAY HELP OTHERS SUBMITTING BIOMARKERS FOR QUALIFICATION BY THE FDA, EXPLAINED STEFAN SULTANA, M.D.,: "THE CUTTING-EDGE IS A LONELY PLACE TO BE BECAUSE NO ONE HAS BEEN DOWN THIS PATH BEFORE, SO WE'RE DEVELOPING NEW SCIENCE AND NEW WAYS OF DOING THINGS WITH THE REGULATORY AGENCIES. HOPEFULLY THE LESSONS WE LEARNED MAKE IT A LOT EASIER FOR OTHER GROUPS TO PURSUE QUALIFICATION OF SAFETY BIOMARKERS."TRACKING KNEE OSTEOARTHRITISMILLIONS OF PEOPLE WORLDWIDE WILL EXPERIENCE OSTEOARTHRITIS AS THEY AGE, AS IT IS THE MOST COMMON DISORDER OF THE JOINTS AND A MAJOR CAUSE OF DISABILITY IN OLDER ADULTS. DESPITE ITS PREVALENCE, THERE REMAINS A LACK OF TOOLS TO ACCURATELY EVALUATE PATIENTS, WHICH MAKES IT DIFFICULT TO DEVELOP NEW TREATMENTS.IN 2018, THE FNIH BIOMARKERS CONSORTIUM LAUNCHED A NEW PROJECT THAT WILL HELP PHYSICIANS AND PATIENTS, LIKE CINDY COPENHAVER, BETTER UNDERSTAND KNEE OSTEOARTHRITIS. RESEARCHERS WILL SEEK REGULATORY QUALIFICATION OF A NEW SET OF IMAGING (I.E., MRI) AND BIOCHEMICAL (I.E., URINE, SERUM) BIOMARKERS THAT PREDICT STRUCTURAL CHANGES IN THE JOINT CAUSED BY KNEE OSTEOARTHRITIS OVER TIME. THE FNIH IDENTIFIED THESE BIOMARKERS THROUGH A PREVIOUS PROJECT AND SHOWED THAT THEY MORE PRECISELY PREDICT AND MONITOR CHANGES IN THE KNEE COMPARED TO THE CURRENT STANDARD THAT USES X-RAY IMAGES. THE ACCEPTANCE OF THESE BIOMARKERS FOR THE DEVELOPMENT OF NEW DRUGS WILL PAVE THE WAY FOR IMPROVED TREATMENT OPTIONS FOR OSTEOARTHRITIS PATIENTS.SHAPING PERSONALIZED CANCER THERAPIESNEARLY EVERYONE HAS A FAMILY MEMBER OR FRIEND AFFECTED BY CANCER. FORTUNATELY, RECENT ADVANCES IN IMMUNOTHERAPIES HAVE SHOWN PROMISING RESPONSES IN CERTAIN CANCER TYPES. WHAT RESEARCHERS STILL NEED TO UNCOVER IS HOW AND WHEN TO BEST PAIR AN IMMUNOTHERAPY TO A SPECIFIC PATIENT.IN 2018, THE FNIH, NIH, FDA AND 12 PHARMACEUTICAL COMPANIES CONTINUED THEIR WORK TO BETTER UNDERSTAND HOW IMMUNOTHERAPIES ARE EFFECTIVE IN SOME PATIENTS AND TO ACCELERATE THE DEVELOPMENT OF NEW TREATMENTS THROUGH THE PARTNERSHIP FOR ACCELERATING CANCER THERAPIES (PACT). LEVERAGING THEIR COLLECTIVE EXPERTISE, CAPABILITIES AND RESOURCES, THE PARTNERS SET OUT TO IDENTIFY AND DEVELOP ROBUST, STANDARDIZED BIOMARKERS AND TESTS THAT WILL SUPPORT THE SELECTION AND CLINICAL TESTING OF IMMUNE-ONCOLOGY AND COMBINATION THERAPIES FOR PATIENTS. THESE BIOMARKERS AND TESTS WILL BE SHARED WITH THE BROADER RESEARCH COMMUNITY SO THAT THEY CAN BE USED EFFECTIVELY IN CLINICAL TRIALS CONDUCTED ANYWHERE IN THE CANCER FIELD."THE PACT TEAM HAS WORKED ACROSS BARRIERS TO BRING DIFFERENT PEOPLE TOGETHER TO DO SOMETHING THAT WOULD BE DIFFICULT TO DO ALONE," EXPLAINED JEFFREY ABRAMS, M.D., DIRECTOR, CLINICAL RESEARCH, DIVISION OF CANCER TREATMENT AND DIAGNOSIS, AND ASSOCIATE DIRECTOR OF THE CANCER THERAPY EVALUATION PROGRAM, NATIONAL CANCER INSTITUTE (NCI), RETIRED. "THE CHALLENGE OF OUR TIME WILL BE TO MAKE IMMUNOTHERAPIES WORK EVEN BETTER FOR INDIVIDUAL PATIENTS TO GENERATE THE RAPID PROGRESS THAT WE'D ALL LIKE TO SEE."EXPANDING THE ACCELERATING MEDICINES PARTNERSHIPTHE ACCELERATING MEDICINES PARTNERSHIP (AMP) HAS SERVED AS AN EFFECTIVE VEHICLE FOR PUBLIC-PRIVATE PARTNERSHIPS IN BIOMEDICAL RESEARCH SINCE 2014. AMP INITIALLY BROUGHT TOGETHER THE FNIH, NIH AND FDA WITH NOT-FOR-PROFIT ORGANIZATIONS AND INDUSTRY TO ACCELERATE EARLY-STAGE DRUG DEVELOPMENT IN ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND THE AUTOIMMUNE DISORDERS RHEUMATOID ARTHRITIS (RA) AND SYSTEMIC LUPUS ERYTHEMATOSUS. BY ENABLING JOINT PLANNING OF RESEARCH IN THE HIGHEST AREAS OF NEED AND SHARING RESOURCES, EXPERTISE AND DATA, AMP HAS MADE SIGNIFICANT PROGRESS IN UNDERSTANDING DISEASE PATHWAYS AT THE MOLECULAR LEVEL AND IN IDENTIFYING NEW TARGETS FOR TREATMENTS. ALL OF THE DATA GENERATED FROM AMP ARE MADE BROADLY AVAILABLE TO THE RESEARCH COMMUNITY THROUGH ONLINE KNOWLEDGE PORTALS FOR USE IN DRUG DISCOVERY AND DEVELOPMENT.IN 2018, THE AMP TEAM EXPANDED WORK IN TWO KEY AREAS:1. LAUNCH OF AMP PARKINSON'S DISEASE (AMP PD): THE NUMBER OF PEOPLE LIVING WITH PARKINSON'S DISEASE IS EXPECTED TO NEARLY DOUBLE BY 2040, ACCORDING TO THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE, AND THERE ARE STILL NO DISEASE-MODIFYING DRUGS (NINDS) APPROVED FOR TREATMENT. THROUGH THE NEW AMP PD PROGRAM, RESEARCHERS WILL TRANSFORM THE CURRENT MODEL FOR DEVELOPING DIAGNOSTICS AND TREATMENTS FOR PATIENTS BY IDENTIFYING AND VALIDATING BIOMARKERS THAT TRACK DISEASE PROGRESSION AND SERVE AS NEW DRUG TARGETS.2. EXTENSION OF AMP RA/LUPUS TO A 6TH YEAR: THIS PROGRAM EXTENSION WILL ENABLE RESEARCHERS TO DEPLOY EMERGING TECHNOLOGIES THAT CAN FURTHER ANALYZE TISSUE, BLOOD AND URINE SAMPLES FROM PATIENTS LIVING WITH RA OR LUPUS. THE PROGRAM WILL CREATE A MORE DETAILED UNDERSTANDING OF THE MOLECULAR NATURE OF THESE DISEASES. BY EXAMINING SAMPLES AT THE SINGLE-CELL LEVEL RESEARCHERS ARE IDENTIFYING THE GENES, PROTEINS AND CHEMICAL PATHWAYS THAT PLAY IMPORTANT ROLES IN THESE DISEASES AND UNCOVERING NEW TARGETS FOR DRUG DEVELOPMENT. 1074653 792028 SEE SCHEDULE O, PROGRAM TWO, EDUCATION, TRAINING AND PATIENT SUPPORT PROGRAMSPROGRAM TWO - EDUCATION, TRAINING AND PATIENT SUPPORT PROGRAMS - THE CRITICAL ROLE OF CLINICIAN-SCIENTISTS CLINICIAN-SCIENTISTS FULFILL AN ESSENTIAL AND UNIQUE ROLE IN MEDICINE. THEY CONDUCT RESEARCH THAT APPLIES BASIC SCIENTIFIC KNOWLEDGE TO CLINICAL PROBLEMS ULTIMATELY HARNESSING DISCOVERY FROM THE LABORATORY AND APPLYING IT DIRECTLY TO PATIENT CARE. YET, THE NUMBER OF THOSE EMBARKING ON CAREERS IN THIS VITALLY IMPORTANT FIELD IS DECLINING.IN 2018, THE FNIH LAUNCHED THE TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTS, MADE POSSIBLE WITH GENEROUS SUPPORT FROM JOHN I. GALLIN, M.D., AND ELAINE K. GALLIN, PH.D., TO RECOGNIZE THE OUTSTANDING CONTRIBUTIONS OF EARLY CAREER CLINICIAN-SCIENTISTS WHOSE WORK HAS THE POTENTIAL TO OR HAS LED TO INNOVATIONS IN PATIENT CARE. THE TRAILBLAZER PRIZE IS AN OPPORTUNITY TO SHINE A LIGHT ON THE ESSENTIAL MEDICAL CONTRIBUTIONS OF CLINICIAN-SCIENTISTS AND INSPIRE THE NEXT-GENERATION TO JOIN THE FIELD.AFTER RECEIVING MORE THAN 100 NOMINATIONS, THE JURY SELECTED THREE FINALISTS: DANIEL BAUER, M.D., PH.D., HARVARD MEDICAL SCHOOL, JAEHYUK CHOI, M.D., PH.D., FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY AND MICHAEL FOX, M.D., PH.D., BETH ISRAEL DEACONESS MEDICAL CENTER, HARVARD MEDICAL SCHOOL. IN OCTOBER, THE FINALISTS JOINED THE FNIH FOR AN EVENT ON CAPITOL HILL TO EXPLAIN THEIR RESEARCH AND OFFER INSIGHTS ABOUT THEIR PROFESSION TO CONGRESSIONAL STAFFERS. THE FNIH ANNUAL FALL BOARD DINNER FOLLOWED THAT EVENING, WHERE THE FNIH ANNOUNCED DR. FOX AS THE PRIZE WINNER FOR PIONEERING INNOVATIVE TECHNIQUES TO MAP HUMAN BRAIN CONNECTIVITY THAT CAN BE TRANSLATED INTO NEW TREATMENTS FOR NEUROLOGICAL DISEASES."THE PURPOSE OF OUR LAB IS TO TRANSLATE HUMAN BRAIN CONNECTIONS INTO NEW PATIENT CARE," EXPLAINED DR. FOX. "AS WE LEARN THAT DIFFERENT SYMPTOMS MAP TO DIFFERENT BRAIN CIRCUITS, WE TAILOR OUR TREATMENTS TO THOSE SYMPTOMS, RATHER THAN TREATING ALL PATIENTS THE SAME WAY. ONE OF MY PATIENTS HAD PARKINSON'S DISEASE AND A MEDICATION REFRACTORY TREMOR. THROUGH DEEP BRAIN STIMULATION THERAPY, HE EXPERIENCED NOT HAVING THE TREMOR FOR THE FIRST TIME IN 12 YEARS."DR. FOX'S WORK EXEMPLIFIES HOW CLINICIAN-SCIENTISTS DRIVE INNOVATIONS FOR PATIENT CARE. THROUGH THE TRAILBLAZER PRIZE, THE FNIH WILL CONTINUE TO SHOWCASE THEIR SIGNIFICANT CONTRIBUTIONS THAT CAN BE LIFE-CHANGING FOR PATIENTS NOW AND IN THE FUTURE.A NEW TOOL WITH POTENTIAL TO ELIMINATE MALARIAFOLLOWING YEARS OF SUCCESS IN REDUCING MALARIA ACROSS THE GLOBE, PROGRESS HAS STALLED. ACCORDING TO THE WORLD HEALTH ORGANIZATION, THERE WERE AN ESTIMATED 219 MILLION CASES OF MALARIA IN 2017, AN INCREASE FROM 217 MILLION IN 2016. REDUCTIONS IN MORTALITY RATES HAVE SIMILARLY PLATEAUED AND SCIENTISTS, COUNTRIES AND COMMUNITIES FIND THEMSELVES AT A CRITICAL JUNCTURE."THERE HAS BEEN LITTLE INNOVATION IN MALARIA CONTROL AND SO FOR THE FIRST TIME WITH THE COMING OF TECHNOLOGY LIKE GENE DRIVE, PARTICULARLY AFTER THE DISCOVERY OF THE GENE EDITING TECHNIQUE CRISPR, MANY OF US STARTED TO BELIEVE THAT WE HAVE A TOOL NOW THAT COULD POTENTIALLY BE REVOLUTIONARY. NONETHELESS, MORE RESEARCH IS NEEDED TO ASSESS BENEFITS AND RISKS. AND THAT'S WHAT WE ARE ASKING OUR SCIENTISTS TO DO," EXPLAINED FREDROS OKUMU, PH.D.GENE DRIVE IS A MECHANISM THAT PROMOTES THE PREFERENTIAL INHERITANCE OF A GENETIC TRAIT TO INCREASE ITS PREVALENCE IN A POPULATION. RECENT ADVANCES IN GENE EDITING ALLOW THIS NATURAL MECHANISM TO BE MIMICKED IN THE LABORATORY. MANY APPLICATIONS OF THIS EMERGING TECHNOLOGY ARE BEING CONSIDERED, INCLUDING ITS USE ON MOSQUITOES TO REDUCE THE TRANSMISSION OF MOSQUITO-BORNE DISEASES, SUCH AS MALARIA. AS THE TECHNOLOGY IS STILL IN ITS EARLY STAGES, IT REQUIRES CAREFUL CONSIDERATION AND ASSESSMENT BEFORE GENE DRIVE PRODUCTS CAN BE FIELD-TESTED AND DEPLOYED.THE FNIH IS WORKING WITH PARTNERS LIKE DR. OKUMU TO FACILITATE IMPORTANT DISCUSSIONS ON GENE DRIVE TECHNOLOGY AMONG VARIOUS STAKEHOLDERS TO DEVELOP AND SHARE BEST PRACTICES, TECHNICAL ADVICE AND TRAINING TO ADVANCE RESPONSIBLE RESEARCH. IN 2018, DR. OKUMO WAS PART OF AN FNIH-LED WORKING GROUP THAT PRESENTED THEIR PAPER AT THE AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE (ASTMH) ANNUAL MEETING, WHICH OUTLINES RECOMMENDATIONS FOR THE SAFE AND ETHICAL TESTING OF GENE DRIVE TECHNOLOGY ON MOSQUITOES TO REDUCE THE BURDEN OF MALARIA TRANSMISSION IN AFRICA. PREVIOUSLY PUBLISHED IN ASTMH'S SCIENTIFIC JOURNAL, THE PAPER PROPOSES A PATHWAY FOR THE RESPONSIBLE DEVELOPMENT AND TESTING OF GENE DRIVE PRODUCTS."OUR INTEREST NOW IS TO ENCOURAGE SCIENTISTS TO INVESTIGATE THE POTENTIAL OF THE TECHNOLOGY," SAID DR. OKUMU. "IF WE DON'T DO SCIENTIFIC RESEARCH ON THIS TECHNOLOGY THEN WE WON'T BE ABLE TO UNDERSTAND IT. GIVEN THE COMPLEXITY ASSOCIATED WITH THIS TOOL, IT IS ONLY RIGHT TO BRING EVERYONE TOGETHER TO TRY TO MAKE SURE PEOPLE ARE SPEAKING THE SAME LANGUAGE. MAYBE FOR THE FIRST TIME, IF WE DO THINGS RIGHT, WE COULD HAVE A TOOL THAT DRAMATICALLY SHIFTS THE NEEDLE TOWARDS THE DREAM OF MALARIA ELIMINATION WHICH HAS BEEN ELUSIVE FOR A LONG TIME." 852380 10000 SEE SCHEDULE O, PROGRAM THREE, PATIENT SUPPORT PROGRAM/CAPITAL PROJECTPROGRAM THREE - PATIENT SUPPORT PROGRAM/CAPITAL PROJECT -RENOVATING A SAFE HAVEN FOR NIH PATIENTS AND FAMILIESPARTICIPATING IN MEDICAL RESEARCH IS OFTEN THE LAST CHANCE FOR PATIENTS TO FIND A NEW, POTENTIALLY LIFE-SAVING THERAPY TO FIGHT THEIR DISEASE. PATIENTS AND THEIR FAMILIES TRAVEL FAR FROM HOME TO ACCESS CLINICAL TRIALS, LEAVING WORK BEHIND TO LIVE IN HOTELS FOR MONTHS A REALITY THAT CAN BE DRAINING, STRESSFUL AND COSTLY.DURING THIS DIFFICULT TIME, THE EDMOND J. SAFRA FAMILY LODGE PROVIDES A HAVEN FOR THESE BRAVE FAMILIES ON THE NIH CAMPUS. ADULT PATIENTS PARTICIPATING IN MEDICAL RESEARCH AT THE NIH CLINICAL CENTER AND THEIR FAMILIES CAN STAY AT THE FAMILY LODGE AT NO COST TO THEM. IN 2018, THE FNIH AND NIH, WITH SUPPORT FROM FNIH BOARD MEMBER LILY SAFRA AND THE EDMOND J. SAFRA FOUNDATION, PARTNERED TO RENOVATE THE FAMILY LODGE, WHICH WAS SHOWING SIGNS OF WEAR AFTER 12 YEARS OF CONTINUOUS USE. THE TEAM DELICATELY BALANCED MINIMIZING DISRUPTION TO THE DAILY OPERATIONS WHILE MAKING ENHANCEMENTS, SUCH AS NEW LIGHTING, PAINT, CARPET AND DRAPERY, FOR THE 34 GUEST ROOMS AND COMMON AREAS."THEY DID A GREAT JOB WITH RENOVATING THE FAMILY LODGE," SAID DAVID HAAS. "IT HAS BEEN AN IMPORTANT PART OF MY FAMILY'S JOURNEY AT THE NIH. FROM TALKING WITH OTHER GUESTS, I HEAR DIFFERENT STORIES ABOUT HOW NIH'S CUTTING-EDGE RESEARCH IS HELPING PEOPLE FROM ALL OVER THE WORLD. IT'S VITALLY IMPORTANT THAT THEY CONTINUE THAT WORK, AND THAT FAMILIES HAVE A PLACE TO STAY NEARBY." 486093 78665 PROGRAM FOUR - MEMORIALS, AWARDS, AND EVENTS 486093 78665 36575014 1 1 0 1 0 1 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 26 0 1 65 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 X 25 24 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD VA NY AL AK AR CA CO CT FL GA HI IL KS KY ME MA MI MS MN NH NJ NM NC ND OH OK OR PA RI SC TN UT WA WV WI NV X X DONALD M HILL 3014356246 11400 ROCKVILLE PIKE SUITE 600 NORTH BETHESDA MD 20852 DR STEVEN M PAUL CHAIRMAN 1.50 X X 0 0 0 DR SOLOMON H SNYDER VICE-CHAIRMAN 0.50 X X 0 0 0 MR STEVEN C MAYER TREASURER 2.00 X X 0 0 0 MRS WILLIAM MCCORMICK BLAIR JR SECRETARY 1.00 X X 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 40.00 X X 472786 0 27500 DR KATHY BLOOMGARDEN BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MRS WILLIAM N CAFRITZ BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR MARIJN DEKKERS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR JAMES H DONOVAN BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL L HERRLING BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR THOMAS R INSEL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR JUDY LANSING KOVLER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR RONALD L KRALL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR FREDA C LEWIS-HALL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR EDISON T LIU BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR JOEL S MARCUS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL M MONTRONE BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DAME JILLIAN SACKLER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MRS LILY SAFRA BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR CHARLES A SANDERS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR FRED SEIGEL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR ELLEN V SIGAL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR RUSSELL W STEENBERG BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL STOFFELS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR SAMUEL O THIER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MS NINA SOLARZ DIRECTOR THROUGH 12/21/18 0.50 X 0 0 0 MR DAVID WHOLLEY SENIOR VP OF RESEARCH PARTNERSHIPS 40.00 X 335826 0 43220 DR STEPHANIE JAMES SENIOR VP OF SCIENCE 40.00 X 329574 0 27500 MR DONALD HILL CHIEF FINANCIAL OFFICER 40.00 X 229912 0 38899 MR KEVIN A KLOCK VP OF OPERATIONS & GENERAL COUNSEL 40.00 X 209068 0 37699 MR ROBERT BALTHASER VICE PRESIDENT OF ADVANCEMENT 40.00 X 156672 0 21666 MS JULIA WOLF-RODDA SENIOR VP OF DEVELOPMENT 40.00 X 216062 0 36799 DR JOSEPH MENETSKI ASSOCIATE VP OF RESEARCH PARTNERSHIPS 40.00 X 215262 0 34519 DR DAVID O'BROCHTA SCIENTIFIC PROGRAM MANAGER 40.00 X 179788 0 32047 DR KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 40.00 X 178232 0 33327 DR STACEY ADAM DIRECTOR OF CANCER 40.00 X 165609 0 22576 DR ROSA CANET AVILES DIRECTOR OF NEUROSCIENCE 40.00 X 163632 0 32170 2852423 0 387922 23 0 1 0 SWOG CTI 24 FRANK LLOYD WRIGHT DRIVE PO BOX ANN ARBOR MI 48105 CONDUCTS CLINICAL TRIAL FOR LUNGMAP 7054078 THE BROAD INSTITUTE INC 415 MAIN STREET CAMBRIDGE MA 02142 PROFESSIONAL SERVICES FOR THE AMP T2DIAB 601496 THE BOSTON CONSULTING GROUP INC PO BOX 75200 CHICAGO IL 60675 PROFESSIONAL SERVICES FOR BUSINESS PLAN 505000 SUSAN A VALLON LTD 4237 LENORE LANE NW WASHINGTON DC 20008 DESIGNING SERVICES FOR SAFRA LODGE 431200 AVID RADIOPHARMACEUTICALS INC 3711 MARKET STREET 7TH FLOOR PHILADELPHIA PA 19104 CONDUCTS CLINICAL TRIAL FOR AMP AD 372500 20 60606 2000000 58384012 116790 60444618 ADMINISTRATIVE FEES 561000 64723 64723 64723 2057158 2057158 90642144 89772633 869511 869511 869511 307550 60606 286264 21286 21286 63457296 64723 0 2947955 15579023 15579023 25597 25597 3798560 3798560 2183183 828884 1304205 50094 4672402 2854419 1805853 12130 497210 263157 222677 11376 837584 482972 336500 18112 448924 196636 252288 168750 132198 36552 56500 56500 78000 78000 159775 159775 7490 1438 6052 21425 2852 18497 76 115225 52803 49196 13226 538714 141058 397656 1567655 1491938 68194 7523 173807 173807 174493 104525 69968 PROGRAM CONTRACTS 11748431 11748431 CONSULTANTS 2023825 1783975 233850 6000 HONORARIA 111150 111150 POSTAGE AND DELIVERY 109230 100598 3805 4827 -2904041 -3125200 200605 20554 42192912 36575014 5395980 221918 25197544 23800394 23480012 17270547 154153 229753 2428720 875296 1653277 1553424 69726056 99554021 221373 485835 120432415 142893974 3704459 3884772 3382073 6070167 1240626 1235000 1617638 1801228 9944796 12991167 X 15970742 18067390 91433211 108642245 3083666 3193172 110487619 129902807 120432415 142893974 21264384 -1849196 0 X X 0 1 X 1 0 X 73905546 33961607 82860385 61322159 60444618 312494315 73905546 33961607 82860385 61322159 60444618 312494315 136924351 175569964 214303 367897 574125 1066052 2057158 4279535 316773850 690452 0.55420 0.53930 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 0 0 0 0 PART II-B, LINE 1: FNIH CONSULTED ITS COMMITTEES OF JURISDICTION ON PUBLIC HEALTH LEGISLATION 2 2500 3100 3197869 1 1 0 1 X 11920726 1032217 -267231 103397 67504 12514811 9704030 1721204 552828 57336 11920726 9501571 11412 243278 52231 9704030 9616660 10356 -100829 24616 9501571 3381374 6271975 11641 48330 9616660 0.71010 0.28990 0 0 1387425 107911 1279514 1041295 767385 273910 1553424 CHARITABLE GIFT ANNUITY 137937 DEFERRED LEASE INCENTIVE 1279514 DEFERRED RENT LIABILITY 383777 1801228 X 62045497 -1849196 310908 -1538288 63583785 159775 -286264 -126489 63457296 42630309 310908 286264 597172 42033137 159775 159775 42192912 PART IV, LINE 2B: AS OF 12/31/2018, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC HELD $1,235,000 IN AGENCY FUNDS FOR FUTURE DISTRIBUTIONS TO THE NATIONAL INSTITUTES OF HEALTH (NIH). THESE FUNDS ARE DESIGNATED BY THE FUNDER(S) FOR SPECIFIC PROJECTS AT THE NIH, AND WILL BE DISBURSED AS NEEDED. PART V, LINE 4: THE FOUNDATION HAS ONE ENDOWMENT THAT IS FUNDED BY MULTIPLE DONORS TO SEED NEW DISCOVERIES AND/OR BE AVAILABLE TO RESPOND TO EPIDEMICS AND FOUNDATION'S UNANTICIPATED NEEDS. THE FOUNDATION'S OTHER ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSE. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS. PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2018 AND 2017. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE -286,264. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE 286,264. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTMAKING 2269532 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 GRANTMAKING 263376 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 0 GRANTMAKING 1265652 0 0 0 0 0 0 3798560 0 3798560 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 799316 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 176803 WIRE TRANSFER EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, RESEARCH 74493 WIRE TRANSFER SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, RESEARCH 257131 WIRE TRANSFER EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, RESEARCH 123050 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 192556 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 85340 WIRE TRANSFER SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, RESEARCH 807224 WIRE TRANSFER SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, RESEARCH 201297 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 670149 WIRE TRANSFER EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, RESEARCH 45833 WIRE TRANSFER EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, RESEARCH 20000 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 345368 WIRE TRANSFER 3 10 0 0 0 0 0 0 PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. X X X X X 1 CHRISTINE K OWENS 1851 N SCOTT STREET 460 ARLINGTON VA 22209 ADVISEMENT ON RELATIONSHIP MANAGEMENT AND ADVISEMENT POLICY 0 0 78000 -78000 78000 -78000 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY 2018 FNIH AWARD CEREMONY 308156 60606 247550 21971 215570 2019 FNIH AWARD CEREMONY 60000 60000 48723 368156 60606 307550 21971 264293 286264 21286 1 BRIGHAM & WOMEN'S HOSPITAL 1620 TREMONT STREET 3RD FLOOR RM BC 3002 BOSTON MA 02120 042312909 501(C)(3) 369870 RESEARCH BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501(C)(3) 224848 RESEARCH CASE WESTERN RESERVE UNIVERSITY NORD HALL SUITE 615 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(C)(3) 357653 RESEARCH CATALYSIS FOUNDATION FOR HEALTH INC 1900 POWELL STREET SUITE 600 EMERYVILLE CA 94608 208602047 501(C)(3) 198596 RESEARCH DUKE UNIVERSITYHUMAN VACCINE INSTITUTE 2200 WEST MAIN STREET SUITE 820 ERWIN SQUARE PLAZA DURHAM NC 27705 560532129 501(C)(3) 227762 RESEARCH FRED HUTCHINSON CANCER RESEARCH 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 350856 RESEARCH FRIENDS OF CANCER RESEARCH 1800 M STREET NW SUITE 1050 SUTH WASHINGTON DC 20036 521983273 501(C)(3) 100000 RESEARCH JOHN HOPKINS UNIVERSITY 615 N WOLFE ST W1100 BALTIMORE MD 21205 150595110 501(C)(3) 212697 RESEARCH NIHCC 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 334272 RESEARCH NIHNCI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858116 170(C)(1) GOVT 911414 RESEARCH NIHNIA 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858117 170(C)(1) GOVT 883053 RESEARCH NIHNIAID 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 3750789 RESEARCH NIHNIAMS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 1967764 RESEARCH NIHNIMH 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 722028 RESEARCH NIHNINDS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 846807 RESEARCH NIHOD 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 216871 RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET 1040 WOLVERINE TOWER ANN ARBOR MI 48109 386006309 170(C)(1) GOVT 772508 AMP-T2 DIABETES. DEPOSIT OF METSIM AND FUSION DATA INTO KNOWLEDGE PORTAL SUTTER BAY HOSPITALS DBA CALIFORNIA PACIFIC MEDICAL CENTER 475 BRANNAN STREET SUITE 220 SAN FRANCISCO CA 94107 940562680 501(C)(3) 44850 RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO MISSION HALL 550 16TH STREET 2ND FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 287500 RESEARCH UNIVERSITY OF SOUTHERN CALIFORNIA SOTO STREET BUILDING 2001 SOTO STREET LOS ANGELES CA 900899235 911642394 501(C)(3) 803151 RESEARCH WESTERN MICHIGAN UNIVERSITY 1903 W MICHIGAN AVENUE KALAMAZOO MI 49008 386007327 501(C)(3) 1044969 RESEARCH UNIVERSITY OF LOUISIANA AT LAFAYETTE 104 UNIVERSITY CIRCLE LAFAYETTE LA 70503 726000820 501(C)(3) 592374 RESEARCH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE PO BOX 1498 NEW YORK NY 10029 136171197 501(C)(3) 165587 RESEARCH WEST VIRGINIA UNIVERSITY FOUNDATION 1 WATERFRONT PLACE 7TH FLOOR PO BOX 1650 MORGANTOWN WV 26507 556017181 501(C)(3) 61320 RESEARCH REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 PO BOX 1450 MINNEAPOLIS MN 55485 416007513 501(C)(3) 47358 RESEARCH REGENTS OF THE U OF CALIFORNIA SAN FRANCISCO MISSION HALL 550 16TH STREET 2ND FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 42064 RESEARCH PRESIDENT AND FELLOWS OF HARVARD COLLEGE PO BOX 415649 BOSTON MA 02241 042103580 501(C)(3) 42062 RESEARCH 27 AWARDS 10 10597 FMV PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE. X X X X X 0 0 0 0 0 0 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 452786 0 20000 0 0 0 27500 0 0 0 500286 0 0 0 MR DAVID WHOLLEY SENIOR VP OF RESEARCH PARTNERSHIPS 325826 0 10000 0 0 0 27500 0 15720 0 379046 0 0 0 DR STEPHANIE JAMES SENIOR VP OF SCIENCE 329574 0 0 0 0 0 27500 0 0 0 357074 0 0 0 MR DONALD HILL CHIEF FINANCIAL OFFICER 229912 0 0 0 0 0 23179 0 15720 0 268811 0 0 0 MR KEVIN A KLOCK VP OF OPERATIONS & GENERAL COUNSEL 209068 0 0 0 0 0 21229 0 16470 0 246767 0 0 0 MR ROBERT BALTHASER VICE PRESIDENT OF ADVANCEMENT 156672 0 0 0 0 0 15638 0 6028 0 178338 0 0 0 MS JULIA WOLF-RODDA SENIOR VP OF DEVELOPMENT 216062 0 0 0 0 0 21729 0 15070 0 252861 0 0 0 DR JOSEPH MENETSKI ASSOCIATE VP OF RESEARCH PARTNERSHIP 215262 0 0 0 0 0 21449 0 13070 0 249781 0 0 0 DR DAVID O'BROCHTA SCIENTIFIC PROGRAM MANAGER 179788 0 0 0 0 0 17977 0 14070 0 211835 0 0 0 DR KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 175732 0 2500 0 0 0 17757 0 15570 0 211559 0 0 0 DR STACEY ADAM DIRECTOR OF CANCER 165609 0 0 0 0 0 16548 0 6028 0 188185 0 0 0 DR ROSA CANET AVILES DIRECTOR OF NEUROSCIENCE 163632 0 0 0 0 0 16600 0 15570 0 195802 0 0 0 X 2 110839 STOCK PRICE X GOODS 1 5950 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 DR. FREIRE, PRESIDENT OF THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC. (FNIH), IS A NON-EXECUTIVE MEMBER OF THE BOARD OF DIRECTORS OF ALEXANDRIA REAL ESTATE EQUITIES (ARE). MR. JOEL MARCUS, CEO AND CHAIRMAN OF ARE IS A NON-EXECUTIVE MEMBER OF THE FNIH BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE DRAFT FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION REQUIRES DIRECTORS, OFFICERS, VOLUNTEER COMMITTEE MEMBERS, AND STAFF MEMBERS TO DISCLOSE REAL AND APPARENT CONFLICTS OF INTEREST FOR THEMSELVES AND THEIR FAMILY MEMBERS AND TO ANNUALLY SIGN A STATEMENT OF COMPLIANCE. AFTER A CONFLICT OR AN APPARENT CONFLICT OF INTEREST HAS BEEN DISCLOSED, THE BOARD OF DIRECTORS OR THE BOARD COMMITTEE, OR THEIR DESIGNEE, SHALL DETERMINE IF THE CONFLICT OF INTEREST OR THE APPEARANCE OF A CONFLICT OF INTEREST EXISTS AND IS MATERIAL AND WILL DECIDE HOW IT IS TO BE MANAGED OR ELIMINATED. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WILL REVIEW AND APPROVE THE SALARIES OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 ALL SUCH DOCUMENTS ARE AVAILABLE UPON REQUEST. IN ADDITION, THE GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE AVAILABLE ON THE FNIH WEBSITE. FORM 990, PART XII, LINE 2C: PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.